Data show that simufilam reduced seizure activity in a preclinical mouse model Presentation also highlights favorable human safety data fro ...

Cassava Sciences Shares Lower Premarket on $40 Million Penalty to Settle Doctored Data Claims Global News Select Sep 27, 2024, 3:48:00 AM ...

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate ...

INmune Bio's ATM offering raises $19M ahead of Phase II results, but disappointing data and dilution signal risks. Read here ...

The saga of Cassava Sciences' development of Alzheimer's disease therapy simufilam has come to its dismal end. The company has reported top-line data from a second phase 3 trial of the drug, which ...

Cassava Sciences Inc receives Investment Bank Analyst Rating Update By Investing.com • Sep 06, 2022 ...

Cassava Sciences is nearing a Phase 3 readout for its Alzheimer's drug, lecanemab, despite facing a scandal involving the SEC. Learn more about the latest updates on donanemab and the company's ...

SAVA SEC Filings Filing Type: Financials Cassava Sciences, Inc. (SAVA) - 10-Q - Quarterly Report SEC FilingsThu, May 08 1 Comment Cassava Sciences, Inc. (SAVA) - 10-K - Annual Report SEC ...

The rankings are conducted by a specialised online survey group passed in the New South Wales province in Australia, which ...

EVERY month, 33-year-old Happy Dismas loses up to four days of work due to debilitating menstrual bleeding caused by uterine ...

DelveInsight's Frontotemporal Dementia Market Insights report includes a comprehensive understanding of current treatment ...